Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta‐analysis. Issue 8 (4th June 2019)

• Record Type: Journal Article
• Authors: Vuong, Huy Gia; Ho, An Thi Nhat; Tran, Thao T. K.; Capdevila, Jaume; Benekli, Mustafa; Nakazawa, Tadao; Katoh, Ryohei; Kondo, Tetsuo
• Is Part Of: Head & neck. Volume 41:Issue 8(2019)
• Page Start: 2823
• Page End: 2829
• Publication Date: 2019-06-04
• Subjects: adverse effect -- drug toxicity -- medullary thyroid carcinoma -- partial response -- sorafenib -- stable disease -- targeted therapy -- VEGFR; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.25832
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Introduction: The aim of this study is to investigate and summarize the treatment efficacy and adverse effects (AEs) of sorafenib in the treatment of metastatic medullary thyroid carcinomas (MTCs). Methods: We included studies reporting the treatment efficacy or drug toxicity of sorafenib as a single therapeutic agent in MTCs. Pooled incidence and its 95% confidence interval (CI) for complete response, partial response (PR), stable disease (SD), and sorafenib‐related AEs were calculated using random‐effect model. Results: Eight trials with 101 metastatic MTCs were included for meta‐analyses. The overall PR and SD were 21% (95% CI = 9‐33) and 58% (95% CI = 41‐75), respectively. Hand‐foot syndrome, diarrhea, alopecia, mucositis, skin rash, fatigue, and hypertension were the most commonly observed AEs. Conclusion: Our results show that sorafenib treatment has a modest effect and might be a candidate treatment in patients with metastatic MTCs who have failed other therapeutic regimens.